International Psoriasis Council
Advancing Knowledge. Improving Care.
PART ONE: LECTURES
Welcome and Introduction
Lars Iversen
Psoriasis in the Last Millennium
Peter van de Kerkhof
Psoriasis and Genetics
Jonathan Barker
Psoriasis and the Immune System
Georg Stingl
Current and Novel Treatments
Filip Rob
Biomarkers in Psoriasis Treatment – Today and in the Future
Lone Skov
Non-pharmacological Management Today and in the Future
Alexander Navarini
Long-term Remission, Inflammatory Memory & Disease Modification
Curdin Conrad
Panel Discussion
All faculty
BREAK
PART TWO: POSTER PRESENTATIONS
Blocking Interleukin-17 in Psoriasis: Real-world Experience from the PsoPlus Cohort
Lisa Schots – Ghent University Hospital, Ghent, Belgium
IL-17A+ Mast Cells in Resolved Psoriasis
Theresa Benezeder – Medical University of Graz, Graz, Austria
Genomic and Epigenomic Rofiling of “Invisible Scar” in Psoriatic Resolved Skin
Ameneh Ghaffarinia – Skin Research Group, Szeged, Hungary
Pathogenic Relationship between Psoriasis and Obesity: An Ex Vivo Study
Giulia Briatico – University of Campania, Napoli, Campania, Italy
Using Single-Cell Transcriptomics to Characterise Early Mechanisms of Disease Remission in Psoriasis
Luc Francis – St. John’s Institute of Dermatology, London, England, United Kingdom
Cytokine Imbalance During Targeted Therapies for Psoriasis and Atopic Dermatitis – The Yin Yang of Th17 and Th2
Francesco Messina – University Hospital CHUV, Lausanne, Switzerland
Defining Paradoxical Psoriasis and Deep Tissue Immune Cell Profiling
David Croitoru – University of Toronto, Toronto, Ontario, Canada
ADJOURN
You must be registered for ESDR to attend the IPC symposium.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
